Walleye Capital LLC Takes $2.54 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Walleye Capital LLC bought a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 99,416 shares of the company's stock, valued at approximately $2,539,000. Walleye Capital LLC owned approximately 0.21% of Enliven Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Quest Partners LLC lifted its position in Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company's stock valued at $37,000 after purchasing an additional 742 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Enliven Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company's stock worth $232,000 after acquiring an additional 3,559 shares during the period. SG Americas Securities LLC bought a new position in Enliven Therapeutics in the third quarter worth approximately $256,000. The Manufacturers Life Insurance Company bought a new position in Enliven Therapeutics in the second quarter worth approximately $322,000. Finally, The Manufacturers Life Insurance Company raised its position in Enliven Therapeutics by 25.6% in the third quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company's stock worth $441,000 after acquiring an additional 3,518 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 847 shares of Enliven Therapeutics stock in a transaction on Friday, October 18th. The shares were sold at an average price of $30.00, for a total value of $25,410.00. Following the completion of the transaction, the insider now directly owns 1,015,188 shares of the company's stock, valued at $30,455,640. This trade represents a 0.08 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Samuel Kintz sold 12,206 shares of Enliven Therapeutics stock in a transaction on Friday, October 4th. The stock was sold at an average price of $27.51, for a total transaction of $335,787.06. Following the completion of the transaction, the chief executive officer now directly owns 1,036,523 shares of the company's stock, valued at $28,514,747.73. The trade was a 1.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 129,195 shares of company stock valued at $3,581,772. Corporate insiders own 29.20% of the company's stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Robert W. Baird increased their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a research report on Friday, November 15th. HC Wainwright restated a "buy" rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Enliven Therapeutics Trading Up 0.4 %

ELVN traded up $0.10 during trading on Wednesday, hitting $23.71. 118,877 shares of the company traded hands, compared to its average volume of 256,671. The company has a market cap of $1.16 billion, a PE ratio of -12.38 and a beta of 1.02. The stock's 50-day simple moving average is $26.79 and its two-hundred day simple moving average is $24.14. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $30.03.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.